Clinical Development of AdVEGF-D Therapy for Refractory Angina
Background
Many patients with coronary artery disease still experience severe chest pain, known as refractory angina, despite existing treatments. A new gene therapy called AdVEGF-D has the potential to help these patients.
About the ReGenHeart Trial
The ReGenHeart trial is a phase 2 study designed to test how safe and effective the AdVEGF-D therapy is for patients with refractory angina. This trial involves:
- Multiple centers and a randomized design to ensure reliable results.
- A comparison between those receiving the therapy and those getting a placebo.
Trial Details
Patients will be divided into groups, with a 2:1 ratio of receiving AdVEGF-D to placebo. The main goals of the trial include:
- Measuring improvements in patients’ walking ability after 6 months.
- Assessing changes in chest pain symptoms at the same time.
Additional measures after 12 months will look at:
- Heart blood flow using advanced imaging techniques.
- Quality of life, use of medications, and rate of serious heart-related events.
Conclusion
This trial will build on earlier positive results, helping to determine if AdVEGF-D therapy is a safe and effective option for patients with severe angina.
Importance of Clinical Trials
Clinical trials are crucial for developing new treatments. Our platform, DocSym, supports healthcare providers by offering a centralized source of information on clinical protocols and research, making it easier for doctors to access the latest standards.
Improving Healthcare Operations
We also provide mobile apps to help with scheduling, monitoring treatments, and telemedicine. These tools simplify patient management and expand services efficiently.
The Role of AI
By integrating AI in clinics, we can enhance workflows, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
